Drug Trial Radar · NCT03945318
Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
103
Actual
Start
Apr 8, 2019
Primary completion
Jun 10, 2026
Study completion Jun 10, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 10, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers and adults with IgA Nephropathy (IgAN).
Conditions
- IgA Nephropathy
Interventions
BION-1301 Single DoseDrug
A single IV infusion infusion of BION-1301 at doses ranging from 10 to 1350 mg, administered once
Placebo Single DoseDrug
A single IV infusion of placebo
BION-1301 Multiple DosesDrug
Part 2: Multiple IV infusions of BION 1301 administered every 2 weeks (Q2W) at doses of 50 mg, 150 mg or 450 mg for up to 3 doses. Part 3: Repeated dosing of BION 1301: 450 mg IV Q2W for ≥24 weeks followed by 600 mg SC Q2W, or 600 mg SC Q2W throughout.
Placebo Multiple DosesDrug
Multiple IV infusions of placebo administered every 2 weeks for up to 3 doses
BION-1301 Single DoseDrug
600 mg SC injection every 2 weeks (Q2W) for retreatment, administered via vials or pre-filled syringes (PFS)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Treatment Emergent Adverse Events (TEAEs) and treatment-emergent serious adverse events (SAEs)Time frame: Up to 276 weeks
- Change from baseline in systolic and diastolic blood pressureTime frame: Baseline and up to 276 weeks.
- Change from baseline in estimated glomerular filtration rate (eGFR)Time frame: Baseline and up to 276 weeks
Locations
16 sites in 3 countries. Site status is shown where the registry gives one.
Amicis Research Center
Northridge, California
Colorado Kidney Care, P.C.
Denver, Colorado
Nephrology Associates of Central Florida
Orlando, Florida
Elixia Tampa, LLC
Tampa, Florida
New York Nephrology
Clifton Park, New York
Chris Sholer, P.C.
Oklahoma City, Oklahoma
Liberty Research Center
Arlington, Texas
Liberty Research Center
Dallas, Texas
Prolato Clinical Research Center
Houston, Texas
Soon Chun Hyang University Hospital Cheonan
Cheonan, Chungcheongnam-do, South Korea
Hallym University Sacred Heart Hospital
Anyang-si, Gyeonggi-do, South Korea
National Health Insurance Service Ilsan Hospital
Goyang-si, Gyeonggi-do, South Korea
Hanyang University Guri Hostpital
Guri-si, Gyeonggi-do, South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
PAREXEL Early Phase Clinical Unit
London, United Kingdom
Liverpool University Hospital NHS Foundation Trust
Liverpool, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.